O
F the primary intracranial neoplasms, gliomas are among those associated with the least improvement in patient survival over the past two decades, despite combination therapy, including surgery, radiation, chemotherapy, and immunotherapy. 23 Monoclonal antibodies (MAb's) to tumor-associated antigens have become important tools in the diagnosis and therapy of various carcinomas, melanoma, and neuroblastoma. 2,5,16-1~ '29-32 In approaches to immunotherapy of cancer patients using MAb's, multiple MAb injections in total doses of up to 400 mg per patient have been well tolerated in spite of the development of patients' immune responses against the MAb's administered. 5'17'3~ Monoclonal antibodies defining glioma-associated antigens that are absent or rarely expressed on normal brain tissues have been described. 3,23,34' 36 Some MAb's have been used successfully in radioimaging and radioimmunotherapy trials in glioma patients. 7,25' 27 However, the use of nonradiolabeled MAb's is more desirable, especially for treatment of central nervous system tumors in children.
Monoclonal antibodies that destroy glioma cells together with mediators of immunological effects, such as effector cells or complement, provide a reagent in unlabeled form, but to our knowledge, have not been described. The reported lymphocytic infiltration of brain tumors favors the use of anti-glioma MAb's that exert their tumoricidal activity through a cell-mediated mechanism/Two MAb's raised against fresh human glioma tissue are described, one mediating antibodydependent cell-mediated cytotoxicity and the other complement-dependent cytotoxicity against cultured glioma cells. These MAb's may have potential for immunotherapy of glioma patients.
Materials and Methods

Tissues and Cell Lines
Fresh tumor and normal tissues obtained from surgical specimens were immediately frozen in liquid nitrogen and stored at -70~
The glioma, melanoma, and carcinoma cell lines used in binding assays are listed in Table 2 and have been described elsewhere. 6, 14, 15, 20, 21, 24, 26 
Production of Hybridomas
Fresh glioma tissue (anaplastic astrocytoma) obtained from one patient was minced and washed in 
Monoelonal Antibody Binding Assays"
All MAb binding assays have been described by us previously. ~',9,15 Binding of MAb's in tissue culture supernatant to frozen acetone-fixed sections of tissues and cytospin preparations of normal bone marrow ceils was tested in immunofluorescence and immunoperoxidase assays, 1' 8 Binding of MAb's to fresh peripheral blood lymphocytes, monocytes, and granulocytes from healthy donors was determined by flow cytometry. 9 Binding of MAb's to the surfaces of cultured tumor cells was determined in radioimmunoassay (RIA). 19
Determination of Immunoglobulin lsotype
Monoclonal antibody isotypes were determined in Ouchterlony immunodiffusion studies] ~
Cytotoxicity Assays
Antibody-dependent cell-mediated cytotoxicity assays with human lymphocytes and monocytes or murine macrophages as effector cells and complementdependent cytotoxicity assays with rabbit complement were performed as described previously. 1~ In all cytotoxicity assays, undiluted tissue culture supernatant from hybridoma cells (specific MAb) or myeloma cells (control antibody) were used, and F39 glioma cells were employed as target cells. Six-to 8-hour 51Cr-release assays were used to test antibody-dependent cell-mediated cytotoxicity reactivities of human peripheral blood lymphocytes and monocytes.~~ Effector:target cell ratios were 50:1. Mouse macrophage-mediated cytotoxicity was tested in methyl-3H-thymidine (3H-TdR)-release assays. 1~ The effector:target cell ratio was 50:1. Monoclonal-antibody-dependent complement-dependent cytotoxicity was tested in 1-hour 5~Cr-release assays with rabbit serum as the source of complement. 12 Spontaneous release of radioactivity by ~tCr-labeled target cells in the absence of effector cells or complement was 1% to 2% (range in different experiments) per hour of incubation, and release by 3H-TdR-labeled target cells was 2% to 7% after a 3-day incubation. Control lysis in the presence of irrelevant MAb and effector cells or complement never exceeded 20% in 5~Cr-release assays and 10% in 3H-TdR-release assays. Percentage specific lysis was calculated for antibodydependent cell-mediated cytotoxicity and complementdependent cytotoxicity assays as described.10-12
Characterization of Antigens
The antigen detected by MAb AS-AY 1 was isolated from detergent extracts of cultured F39 glioma cells by immunoaffinity chromatography on Sepharose columns coupled with MAb AS-AYlY Sodium dodecyl sulfate-gel electrophoresis and Western blotting analysis of the immunoaffinity-purified antigen were pertbrmed as previously described. 22' 35
Results
Binding Reactivity of MAb's to Fresh Tissues
Seven MAb's derived from one mouse were selected for detailed study because of their high-level reactivity in immunoperoxidase assay with most of the glioma tissues (total of 26 specimens) tested and the absence of reactivity with any of the four different bone marrow specimens (Table 1) AY2 is shown in Fig. 1 . Each of the MAb's bound to neurofibromas and leiomyomas, and two MAb's also bound to some of the medulloblastoma tissues included ( Table 1) . None of the seven MAb's bound to tissues of two colon carcinomas and one ovarian carcinoma; however, they did bind in various degrees to melanoma tissues. Four of the seven MAb's did not react with any of the four normal brain specimens tested, whereas three MAb's bound to one or two of these specimens. All seven MAb's were nonreactive with two different specimens of normal skin.
Reactivity of MAb's to Cell Surfaces of Cultured Tumor Cells and Fresh Peripheral Blood Cells
All seven MAb's were tested by RIA for binding to the surfaces of live cultured glioma cells. Monoclonal antibodies AS-AY1 (IgG~) and AS-AY2 (IgM) bound to all five glioma cell lines tested (Table 2) , whereas the other five MAb's showed binding to only one or none of the five cell lines (not shown). The two surfacereactive MAb's were analyzed for binding to various cell lines of tissue origin other than glioma (Table 2) . They bound to one of two (AS-AY1) and two of two (AS-AY2) melanoma cell lines but did not bind to any of the carcinoma lines derived from colon, ovary, cervix, bladder, pancreas, breast, prostate, lung, or stomach. In flow cytometry with fresh peripheral blood cells from two healthy donors, MAb AS-AY1 bound to 90% of the lymphocytes and granulocytes but not to monocytes, whereas MAb AS-AY2 did not react to any of these cells (results not shown). The reactivity of MAb AS-AYI in these assays contrasts with the absence of reactivity of this MAb to bone marrow cells (Table 1) . This discrepancy may be explained by differences in the assay procedures. It is possible that the antigen defined by MAb AS-AY1 is fixative-labile which may prevent its detection on fixed bone marrow cells.
MAb Reactivity to Fixed Cells
Of the seven MAb's tested, only MAb AS-AY2 showed reactivity with cultured glioma cells fixed in Bouin's fixative (results not shown).
Cytotoxic Reactivity of MAb's
Since MAb's AS-AY1 and AS-AY2 bound to the surfaces of glioma cells, they were tested for reactivity in antibody-dependent cell-mediated cytotoxicity assay with human and murine effector cells and complementdependent cytotoxieity assay with rabbit complement. Monoclonal antibody AS-AY1 induced antibody-dependent cell-mediated cytotoxicity with murine macrophages and human lymphocytes but not with human monocytes; however, MAb AS-AY2 was highly reactive in complement-dependent cytotoxicity (Table 3) .
Antigens Defined by MAb's
Western blotting analysis of affinity-column-purified antigen recognized by MAb AS-AY 1 identified a 220-kD protein (Fig. 2, lanes a and b) . The MAb did not react to control protein derived from antigen-negative colon carcinoma cells LS-180 (Fig. 2, lane c) . Present investigations are aimed at identifying the antigen defined by M A b AS-AY2.
Discussion
Seven MAb's that show high-level reactivity with h u m a n glioma tissues are described here. Four of these bind exclusively to neuroectodermal tumors, melanomas, and leiomyomas but not to carcinomas or normal cells derived from brain, skin, bone marrow, or peripheral blood. These four MAb's might therefore be useful for the immunohistochemical characterization of malignant gliomas. The MAb's b o u n d preferentially to high-grade gliomas (not shown). Three MAb's also b o u n d to some of the medulloblastomas included. The one MAb (AS-AY2) that reacted with fixed glioma cells should be especially useful in immunocytochemical tissue diagnosis.
Two of our MAb's, AS-AY1 and AS-AY2, mediated antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, respectively, against cultured glioma cells. Monoclonal antibody AS-AY1 is of IgG~ isotype and its interaction with m u r i n e macrophages and h u m a n lymphocytes is consistent with our previous report on IgG~ MAb's in the melanom a and gastrointestinal carcinoma systems.l~ Although MAb AS-AY1 binds to peripheral blood cells and a few normal brain tissues, these reactivities were much weaker than the reactivity of the MAb to brain-tumor cells. This relative difference in binding reactivity of the MAb suggests its potential use in clinical trials since cell-surface antigen/antibody density has been shown to be a determining factor in tumor destruction by MAb. 13 Anti-colorectal carcinoma MAb CO 17-1A, which binds strongly to colorectal tumors but weakly to normal colonic mucosa, 14 has been administered to several hundred patients without producing side effects that could be attributed to the reactivity of this MAb with normal colonic tissues. 3j Furthermore, the existence of a blood-brain barrier to normal brain cells and the possibility of enhanced vascular permeability in tumors (although this remains a controversial issue) 3 may further contribute to the differential binding of MAb to brain-tumor tissues as compared to normal brain.
The other cell-surface reactive MAb, AS-AY2, differs from MAb AS-AY 1 in two respects: 1) consistent with its IgM isotype, ~~ it mediates complement-dependent cytotoxicity and not antibody-dependent cell-mediated cytotoxicity; and 2) it does not bind to any of the normal tissues tested. However, the high molecular weight of IgM MAb's may prohibit their extravascular distribution in tumor tissues. Therefore, efforts are underway to isolate isotypic class-switch variant cells of hybridoma AS-AY2, as we have done for anti-colorectal carcinoma hybridoma CO 19-9. 33 The highly specific reactivity of this MAb with gliomas and medulloblastomas and the demonstration of its cytotoxic reactivity in vitro make it an excellent candidate for approaches to immunotherapy of human brain tumors.
